United Therapeutics Corporation Deferred Foreign Income Tax Expense (Benefit)
United Therapeutics Corporation (UTHR) reported Deferred Foreign Income Tax Expense (Benefit) of -$500.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2026-02-25
- United Therapeutics Corporation deferred foreign income tax expense (benefit) for fiscal 2025 was -$500.00K.
- United Therapeutics Corporation deferred foreign income tax expense (benefit) for fiscal 2024 was $0.00.
- United Therapeutics Corporation deferred foreign income tax expense (benefit) for fiscal 2023 was -$500.00K.
- United Therapeutics Corporation deferred foreign income tax expense (benefit) for fiscal 2015 was $194.00K.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | -$500.00K 10-K · filed 2026-02-25 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-25 |
| 2023-12-31 | -$500.00K 10-K · filed 2026-02-25 |
| 2015-12-31 | $194.00K 10-K · filed 2016-02-25 |
| 2014-12-31 | -$225.00K 10-K · filed 2016-02-25 |
| 2013-12-31 | -$1.05M 10-K · filed 2016-02-25 |
| 2012-12-31 | $182.00K 10-K · filed 2015-02-24 |
| 2011-12-31 | $641.00K 10-K · filed 2014-02-25 |
| 2010-12-31 | -$1.29M 10-K · filed 2013-02-26 |
| 2009-12-31 | $168.00K 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |